ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.492,49
1,22%
S&P 500
5.459,10
1,11%
US Dollar vs BRL
5,6561
0,00%
Bitcoin
67.883,20
-0,04%
Brent Oil
79,745
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. argenx SE (ARGX)

  7. argenx SE (ARGX) Notícias

ARGX argenx SE

494,46
8,13 (1,67%)
26 Jul 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
argenx SE ARGX NASDAQ Recibo de Depósito
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
8,13 1,67% 494,46 18:30:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
476,04 473,67 495,50 494,46 486,33
mais cotações »

Notícias Recentes

Data Hora Fonte Título
25/07/202402:00GLOBEargenx Reports Half Year 2024 Financial Results and Provides..
18/07/202402:00GLOBEargenx to Report Half Year 2024 Financial Results and Second..
16/07/202401:30GLOBEargenx and Zai Lab Announce Approval of Efgartigimod Alfa..
16/07/202401:15BWZai Lab and argenx Announce Approval of Efgartigimod Alfa..
25/06/202417:30GLOBEargenx Highlights Breadth of Autoimmune Pipeline with New..
21/06/202417:50GLOBEargenx Announces FDA Approval of VYVGART Hytrulo for Chronic..
17/06/202402:00GLOBEargenx to unveil its ‘Vision 2030: Taking Breakthrough..
04/06/202402:00GLOBEargenx to Present at Goldman Sachs 45th Annual Global..
09/05/202402:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
07/05/202418:30GLOBEargenx announces results of Annual General Meeting of..
07/05/202402:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/05/202402:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/04/202402:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/03/202403:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/03/202417:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/03/202403:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07/03/202418:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/02/202403:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/02/202403:00GLOBEargenx to Present at Upcoming Investor Conferences
22/02/202403:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/02/202403:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/01/202403:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/01/202403:00GLOBEargenx Highlights 2024 Strategic Priorities
02/01/202403:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202314:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
20/12/202303:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202313:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
28/11/202309:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
28/11/202303:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202309:40GLOBEargenx Announces European Commission Approval of..
01/11/202303:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
31/10/202303:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202302:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/09/202302:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/09/202302:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/08/202302:00GLOBEargenx to Present at Upcoming Investor Conferences

Seu Histórico Recente

NASDAQ
ARGX
argenx
ASX
EDC
Eildon Capital
FX
NZDZAR
NZD vs ZAR
BIT
F37635
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados